# EDGAR Filing Document

**Accession Number:** 0001930214
**File Stem:** 0001213900-25-127135
**Filing Date:** 2025-12
**Character Count:** 25780
**Document Hash:** c0a2f4d831d36c70921acc74182837e1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-127135.hdr.sgml**: 20251231

**ACCESSION NUMBER**: 0001213900-25-127135

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251231

**DATE AS OF CHANGE**: 20251231

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Minerva Neurosciences, Inc.
- **CENTRAL INDEX KEY:** 0001598646
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 260784194
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88240
- **FILM NUMBER:** 251617723

**BUSINESS ADDRESS:**
- **STREET 1:** 1500 DISTRICT AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 617-600-7373

**MAIL ADDRESS:**
- **STREET 1:** 1500 DISTRICT AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vivo Opportunity Fund Holdings, L.P.
- **CENTRAL INDEX KEY:** 0001930214

**ORGANIZATION NAME:**
- **EIN:** 873802421
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** 6506880818

**MAIL ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

## Exhibit 99.1

**Exhibit 99.1**

**Joint Filing Agreement**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

---

| | |
|:---|:---|
| Date: December 31, 2025 | Date: December 31, 2025 |
| **Vivo Opportunity Fund Holdings, L.P.** | **Vivo Opportunity Fund Holdings, L.P.** |
| /s/ Kevin Dai | /s/ Kevin Dai |
| Name: | Kevin Dai |
| Title: | Managing Member of Vivo Opportunity, LLC, General Partner |
| **Vivo Opportunity, LLC** | **Vivo Opportunity, LLC** |
| /s/ Kevin Dai | /s/ Kevin Dai |
| Name: | Kevin Dai |
| Title: | Managing Member |
| **Vivo Opportunity Cayman Fund, L.P.** | **Vivo Opportunity Cayman Fund, L.P.** |
| /s/ Kevin Dai | /s/ Kevin Dai |
| Name: | Kevin Dai |
| Title: | Managing Member of Vivo Opportunity Cayman, LLC, General Partner |
| **Vivo Opportunity Cayman, LLC** | **Vivo Opportunity Cayman, LLC** |
| /s/ Kevin Dai | /s/ Kevin Dai |
| Name: | Kevin Dai |
| Title: | Managing Member |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Minerva Neurosciences, Inc.

**Title of Class of Securities:** Common Stock, par value $0.0001 per share

**CUSIP Number:** 603380205

**Date of Event Which Requires Filing of this Statement:** 12/23/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Vivo Opportunity Fund Holdings, L.P. | Names of Reporting Persons<br>Vivo Opportunity Fund Holdings, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>8591572.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>8591572.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>8591572.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>8591572.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.99% | Percent of Class Represented by Amount in Row (9)<br>9.99% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The reported share amount represents an aggregate of (i) 3,925,900 shares of common stock, par value $0.0001 per share (the "Common Stock") of Minerva Neurosciences, Inc. (the "Issuer"), which were converted automatically from 8,300 shares of the Issuer's Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") on December 23, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 782 shares of Series A Preferred Stock, which are convertible into 369,886 shares of Common Stock, and (iii) Preferred Tranche A Warrant to purchase an aggregate of 9,082 shares of Series A Preferred Stock, which are convertible into 4,295,786 shares of Common Stock. The reported share amount excludes Preferred Tranche B Warrant to purchase an aggregate of 4,541 shares of Series A Preferred Stock, which are convertible into 2,147,893 shares of Common Stock, because the Preferred Tranche B Warrant is not exercisable within 60 days hereof.  All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

The percentage reported in row 11 herein is based on 43,274,398 shares of Common Stock of the Issuer outstanding as reported on the registration statement on Form S-3 filed with the Securities Exchange Commission (the "SEC") on December 23, 2025. The Series A Preferred Stock contains a provision that prevents these securities from being converted into shares of Common Stock, if such conversion would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein include (i) 369,886 shares of Common Stock convertible from 782 shares of Series A Preferred Stock and (ii) 4,295,786 shares of Common Stock convertible from 9,082 shares of Series A Preferred Stock that are exercisable from the Preferred Tranche A Warrant, without giving effect to the blocking provisions.

---

| 1. | Names of Reporting Persons<br>Vivo Opportunity, LLC | Names of Reporting Persons<br>Vivo Opportunity, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>8591572.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>8591572.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>8591572.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>8591572.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.99% | Percent of Class Represented by Amount in Row (9)<br>9.99% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The reported share amount represents an aggregate of (i) 3,925,900 shares of Common Stock of the Issuer, which were converted automatically from 8,300 shares of the Issuer's Series Preferred Stock on December 23, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 782 shares of Series A Preferred Stock, which are convertible into 369,886 shares of Common Stock, and (iii) Preferred Tranche A Warrant to purchase an aggregate of 9,082 shares of Series A Preferred Stock, which are convertible into 4,295,786 shares of Common Stock. The reported share amount excludes Preferred Tranche B Warrant to purchase an aggregate of 4,541 shares of Series A Preferred Stock, which are convertible into 2,147,893 shares of Common Stock, because the Preferred Tranche B Warrant is not exercisable within 60 days hereof. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

The percentage reported in row 11 herein is based on 43,274,398 shares of Common Stock of the Issuer outstanding as reported on the registration statement on Form S-3 filed with the SEC on December 23, 2025. The Series A Preferred Stock contains a provision that prevents these securities from being converted into shares of Common Stock, if such conversion would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein include (i) 369,886 shares of Common Stock convertible from 782 shares of Series A Preferred Stock and (ii) 4,295,786 shares of Common Stock convertible from 9,082 shares of Series A Preferred Stock that are exercisable from the Preferred Tranche A Warrant, without giving effect to the blocking provisions.

---

| 1. | Names of Reporting Persons<br>Vivo Opportunity Cayman Fund, L.P. | Names of Reporting Persons<br>Vivo Opportunity Cayman Fund, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>868428.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>868428.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>868428.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>868428.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.99% | Percent of Class Represented by Amount in Row (9)<br>9.99% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The reported share amount represents an aggregate of (i) 396,847 shares of Common Stock of the Issuer, which were converted automatically from 839 shares of the Issuer's Series Preferred Stock on December 23, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 79 shares of Series A Preferred Stock, which are convertible into 37,367 shares of Common Stock, and (iii) Preferred Tranche A Warrants to purchase an aggregate of 918 shares of Series A Preferred Stock, which are convertible into 434,214 shares of Common Stock. The reported share amount excludes Preferred Tranche B Warrant to purchase an aggregate of 459 shares of Series A Preferred Stock, which are convertible into 217,107 shares of Common Stock, because the Preferred Tranche B Warrant is not exercisable within 60 days hereof. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.

The percentage reported in row 11 herein is based on 43,274,398 shares of Common Stock of the Issuer outstanding as reported on the registration statement on Form S-3 filed with the SEC on December 23, 2025.  The Series A Preferred Stock contains a provision that prevents these securities from being converted into shares of Common Stock, if such conversion would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein include (i) 37,367 shares of Common Stock convertible from 79 shares of Series A Preferred Stock and (ii) 434,214 shares of Common Stock convertible from 918 shares of Series A Preferred Stock that are exercisable from the Preferred Tranche A Warrant, without giving effect to the blocking provisions.

---

| 1. | Names of Reporting Persons<br>Vivo Opportunity Cayman, LLC | Names of Reporting Persons<br>Vivo Opportunity Cayman, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>868428.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>868428.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>868428.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>868428.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.99% | Percent of Class Represented by Amount in Row (9)<br>9.99% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The reported share amount represents an aggregate of (i) 396,847 shares of Common Stock of the Issuer, which were converted automatically from 839 shares of the Issuer's Series Preferred Stock on December 23, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 79 shares of Series A Preferred Stock, which are convertible into 37,367 shares of Common Stock, and (iii) Preferred Tranche A Warrants to purchase an aggregate of 918 shares of Series A Preferred Stock, which are convertible into 434,214 shares of Common Stock. The reported share amount excludes Preferred Tranche B Warrant to purchase an aggregate of 459 shares of Series A Preferred Stock, which are convertible into 217,107 shares of Common Stock, because the Preferred Tranche B Warrant is not exercisable within 60 days hereof. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.

The percentage reported in row 11 herein is based on 43,274,398 shares of Common Stock of the Issuer outstanding as reported on the registration statement on Form S-3 filed with the SEC on December 23, 2025. The Series A Preferred Stock contains a provision that prevents these securities from being converted into shares of Common Stock, if such conversion would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein include (i) 37,367 shares of Common Stock convertible from 79 shares of Series A Preferred Stock and (ii) 434,214 shares of Common Stock convertible from 918 shares of Series A Preferred Stock that are exercisable from the Preferred Tranche A Warrant, without giving effect to the blocking provisions.

---

**Item 1(a). Name of Issuer:**
Minerva Neurosciences, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
1500 District Avenue, Burlington, MA 01803

**Item 2(a). Name of Person Filing:**
Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC

Vivo Opportunity Cayman Fund, L.P. and its General Partner Vivo Opportunity Cayman, LLC

**Item 2(b). Address of Principal Business Office:**
192 Lytton Avenue, Palo Alto, CA 94301

**Item 2(c). Citizenship:**
Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership.

Vivo Opportunity, LLC is a Delaware limited liability company.

Vivo Opportunity Cayman Fund, L.P. is a Cayman Islands limited partnership.

Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**Item 2(e). CUSIP Number:**
603380205

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Vivo Opportunity, LLC may be deemed to beneficially own an aggregate of 8,591,572 shares of the Issuer's securities, consisting of (i) 3,925,900 shares of Common Stock of the Issuer, which were converted automatically from 8,300 shares of the Issuer's Series Preferred Stock on December 23, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 782 shares of Series A Preferred Stock, which are convertible into 369,886 shares of Common Stock, and (iii) Preferred Tranche A Warrants to purchase an aggregate of 9,082 shares of Series A Preferred Stock, which are convertible into 4,295,786 shares of Common Stock. The reported share amount excludes Preferred Tranche B Warrant to purchase an aggregate of 4,541 shares of Series A Preferred Stock, which are convertible into 2,147,893 shares of Common Stock, because the Preferred Tranche B Warrant is not exercisable within 60 days hereof.  The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
Vivo Opportunity Cayman, LLC may be deemed to beneficially own an aggregate of 868,428 shares of the Issuer's securities, consisting of (i) 396,847 shares of Common Stock of the Issuer, which were converted automatically from 839 shares of the Issuer's Series Preferred Stock on December 23, 2025, following the Issuer's receipt of the approval of its stockholders of such conversion, (ii) 79 shares of Series A Preferred Stock, which are convertible into 37,367 shares of Common Stock, and (iii) Preferred Tranche A Warrants to purchase an aggregate of 918 shares of Series A Preferred Stock, which are convertible into 434,214 shares of Common Stock. The reported share amount excludes Preferred Tranche B Warrant to purchase an aggregate of 459 shares of Series A Preferred Stock, which are convertible into 217,107 shares of Common Stock, because the Preferred Tranche B Warrant is not exercisable within 60 days hereof.  These securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
The Series A Preferred Stock contains a provision that prevents these securities from being converted into shares of Common Stock, if such conversion would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in this Item 4 herein represent the number of shares of Common Stock that would be issuable upon full conversion of the Series A Preferred Stock and the full exercise of Tranche A Warrant, without giving effect to the blocking provisions.

**(b) Percent of class:**

Vivo Opportunity Fund Holdings, L.P.: 9.99%
Vivo Opportunity, LLC: 9.99%
Vivo Opportunity Cayman Fund, L.P.: 9.99%
Vivo Opportunity Cayman, LLC: 9.99%
The percentage reported in this Item 4(b) is based on 43,274,398 shares of Common Stock of the Issuer outstanding as reported on the registration statement on Form S-3 filed with the Securities Exchange Commission on December 23, 2025.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

Vivo Opportunity Fund Holdings, L.P.: 8,591,572 shares
Vivo Opportunity, LLC: 8,591,572 shares
Vivo Opportunity Cayman Fund, L.P.: 868,428 shares
Vivo Opportunity Cayman, LLC: 868,428 shares

**(ii) Shared power to vote or to direct the vote:**

0

**(iii) Sole power to dispose or to direct the disposition of:**

Vivo Opportunity Fund Holdings, L.P.: 8,591,572 shares
Vivo Opportunity, LLC: 8,591,572 shares
Vivo Opportunity Cayman Fund, L.P.: 868,428 shares
Vivo Opportunity Cayman, LLC: 868,428 shares

**(iv) Shared power to dispose or to direct the disposition of:**

0

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Vivo Opportunity Fund Holdings, L.P.**

**Date:** 12/31/2025

**By:** /s/ Kevin Dai

**Name & Title:** Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner

**Vivo Opportunity, LLC**

**Date:** 12/31/2025

**By:** /s/ Kevin Dai

**Name & Title:** Kevin Dai/Managing Member

**Vivo Opportunity Cayman Fund, L.P.**

**Date:** 12/31/2025

**By:** /s/ Kevin Dai

**Name & Title:** Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner

**Vivo Opportunity Cayman, LLC**

**Date:** 12/31/2025

**By:** /s/ Kevin Dai

**Name & Title:** Kevin Dai/Managing Member